摘要
胰高血糖素样肽-1(GLP-1)受体激动剂在2型糖尿病治疗中的作用得到广泛认可,为了提高其疗效和安全性,近年来出现了许多分子改造制剂,希望通过几种胃肠激素之间的机制互补以达到更好的效果。Tirzepatide作为一种新型GLP-1/葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂,已被多项研究证实能够控制血糖、减轻体重,并在慢性神经退行性疾病及非酒精性脂肪性肝炎的治疗上具有潜在应用价值。其疗效及安全性优于GLP-1受体激动剂,有着广阔的应用前景。
The role of glucagon-like peptide(GLP-1)receptor agonists in the treatment of type 2 diabetes mellitus has been widely recognized.In order to improve their efficacy and safety,a number of molecularly modified agents have emerged in recent years,hoping to achieve better results through the mechanism complementation between several gastrointestinal hormones.As a novel GLP-1/gastric inhibitory peptide(GIP)dual receptor agonist,Tirzepatide has been proved by many studies to be able to control blood glucose,reduce body weight,and has potential application value in the treatment of chronic neurodegenerative diseases and non-alcoholic steatohepatitis.Its efficacy and safety are superior to GLP-1 receptor agonists,and it has broad application prospects.
作者
史雨清
杨昱
李宸
王昆
Shi Yuqing;Yang Yu;Li Chen;Wang Kun(Nanjing Medical University Graduate School,Nanjing 211166,China;Department of Endocrinology and Metabolism,the Affiliated Jiangning Hospital of Nanjing Medical University,Nanjing 211100,China)
出处
《国际内分泌代谢杂志》
2021年第6期645-648,共4页
International Journal of Endocrinology and Metabolism
基金
国家自然科学基金(82000762)。
